Stories

War changes the meaning of cigarettes. What may look like a simple consumer product can become a coping mechanism, a source of routine and even a form of social currency under extreme stress. That reality does not make smoking safe, but it does show why public health must understand behaviour before trying to control it. Harm reduction starts by recognising why people use nicotine — especially when life is shaped by trauma, pressure and uncertainty.

Europe is moving towards a more restrictive era for safer nicotine products — and adult smokers could pay the price. A new wave of prohibition may be presented as protection, but it risks making legal, lower-risk alternatives harder to access while cigarettes remain widely available. The setback is not only regulatory; it is a failure to distinguish between nicotine use and smoking-related harm. Europe needs a course correction before fear-based policy locks smokers out of better options.

The UK risks sending smokers a dangerous message: cigarettes are familiar, but safer alternatives are suspect. Intensifying anti-vaping campaigns may feel protective, yet it can deepen confusion about relative risk and make switching less attractive. Adult smokers need accurate information, not fear-based communication that blurs the difference between smoke and vapour. Public health should be making the escape from cigarettes clearer, not cloudier.

Europe’s review of the Tobacco Products Directive is not only a health policy question — it is also a test of whether regulation can keep pace with innovation. If lower-risk nicotine products are treated through the same restrictive lens as cigarettes, consumers may lose access to better alternatives while responsible businesses face unnecessary barriers. Evidence should guide the revision, not fear of new technology. A smarter framework would protect young people, support adult smokers who want to switch and allow innovation to reduce harm.

For the first time, the FDA has authorised modified risk claims for nicotine pouches — a milestone that goes beyond one product category. It signals that regulators can recognise a basic public health principle: smoke-free products should not be treated as if they carry the same risks as cigarettes. Clear, evidence-based communication can help adult smokers understand where risk actually lies and make better decisions. International tobacco policy should learn from this shift and regulate nicotine according to harm, not habit.

Ibero-America stands at a turning point in tobacco control. The region can continue with policies that treat all nicotine products as the same, or it can build a more effective model based on risk, evidence and real-world outcomes. Smoking remains the central problem, and lower-risk alternatives should be part of the conversation rather than pushed to the margins. The future of tobacco control should be practical, transparent and focused on reducing disease — not simply controlling nicotine.

Media, politicians, and NGOs funded by Bloomberg have successfully spread misinformation about vaping, leading to a majority believing it is as harmful as smoking. This has caused confusion and made some switch back to smoking. Misinformation impacts public health, hindering harm reduction efforts. Despite evidence showing vaping is less harmful and a useful tool to quit smoking, misconceptions persist. The focus should be on real-world results, not anti-nicotine ideology. The alarming trend may lead to increased smoking rates. It is crucial to address misconceptions and promote accurate information to protect public health.

International health experts presented a five-point plan for a smoke-free Europe amid concerns about policy reversals on tobacco control. They advocate for prioritizing reducing cigarette smoking, learning from Sweden's harm reduction success, regulating products based on relative risks, enhancing youth protections, and harmonizing a framework supporting harm reduction. The plan aims to prevent setbacks in achieving a tobacco-free generation by focusing on the dangers of combustible cigarettes. Dr. Delon Human emphasizes the need to differentiate nicotine products' risks and highlights the potential harm of ineffective policies. The submission by Smoke Free Sweden urges the European Commission to consider harm reduction in tobacco regulation.

Quitting smoking is rarely an individual journey. The benefits extend far beyond the smoker, improving the health, relationships and quality of life of partners, children and loved ones. Smoke-free alternatives can help create healthier homes, more shared time and fewer harms from secondhand smoke. Harm reduction is not just about saving one life — it can improve the wellbeing of entire families.

Tobacco harm reduction is harm reduction. The principle is the same: reduce risk, respect autonomy and meet people where they are, rather than demanding abstinence as the only acceptable outcome. For people who smoke, access to lower-risk nicotine products can offer a practical route away from combustible tobacco. Public health should apply harm reduction consistently — including when the substance is nicotine.